X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: Ultragenyx Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2023
Details:
UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: Ultragenyx Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
MPH966 (alvelestat) is an oral drug that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease. It acts to inhibit the neutrophil elastase enzyme and Mereo believes that it has the potential to protect AATD patients from further lung damage.
Lead Product(s): Alvelestat
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MPH-966
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Alvelestat (MPH966) is an oral drug that is being researched in people for the treatment of severe Alpha-1 antitrypsin deficiency (AATD) and Bronchiolitis Obliterans Syndrome (BOS).
Lead Product(s): Alvelestat
Therapeutic Area: Genetic Disease Product Name: MPH-966
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Alvelestat (MPH966) is an investigational oral neutrophil elastase inhibitor that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease.
Lead Product(s): Alvelestat
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MPH-966
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
The multicenter ACTIVATE study is designed to evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics of MPH-313 (etigilimab), Mereo’s proprietary anti-TIGIT antibody, in combination with a PD-1 inhibitor, nivolumab, with dosing every two weeks.
Lead Product(s): Etigilimab,Nivolumab
Therapeutic Area: Oncology Product Name: MPH-313
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Setrusumab (UX143) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the activity of bone-forming cells.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: Ultragenyx Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
Treatment of MPH-313 (etigilimab) in combination with nivolumab has shown preliminary efficacy across multiple tumor types with 2 complete responses, 4 partial responses, and 10 stable disease for an ORR of 15.8% and DCR of 42.1% in heavily pre-treated.
Lead Product(s): Etigilimab,Nivolumab
Therapeutic Area: Oncology Product Name: MPH-313
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
The combination of MPH-313 (etigilimab) and nivolumab has been safe and well tolerated, with an overall response rate (ORR) of 11% and disease control rate (DCR) of 44% with no new safety signals observed to-date.
Lead Product(s): Etigilimab,Nivolumab
Therapeutic Area: Oncology Product Name: MPH-313
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
MPH-966 (alvelestat) is an oral drug that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease. Lung disease is the most common impact of AATD in adults.
Lead Product(s): Alvelestat
Therapeutic Area: Genetic Disease Product Name: MPH966
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
